[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641224":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":11,"responsibleParty":35,"collaborators":11,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":11,"eligibilityCriteria":44,"healthyVolunteers":41,"sex":45,"minAge":46,"maxAge":11,"enrollmentInfo":47,"targetDuration":11,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":59,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":11},{"fullName":5,"class":6},"Helwan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continuous infusion of cefazolin","EXPERIMENTAL",null,[13],"Drug: Cefazolin 2 g Infusion",{"label":15,"type":16,"description":11,"interventionNames":17},"Intermittent cefazolin injection","ACTIVE_COMPARATOR",[18],"Drug: Cefazolin 2 GM Injection",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Cefazolin 2 g Infusion","Intraoperative continuous infusion (CI) of cefazolin",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Cefazolin 2 GM Injection","Administration of cefazolin 2 gm 30 minutes pre-surgery",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Heba A Abdeen","CONTACT","0201003403231","hebabdeen89@gmail.com",{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Hebatallah Ali Abdeen","Principal Investigator","100641224","phase-4-continuous-infusion-versus-intermittent-iv-bolus-of-cefazolin-prevention-of-surgical-site-infection-during-orthopedic-surgeries-in-egyptian-patients-100641224",false,"NCT07655596","Continuous Infusion Versus Intermittent IV Bolus of Cefazolin: Prevention of Surgical Site Infection During Orthopedic Surgeries in Egyptian Patients.","Inclusion Criteria:\n\n* Orthopaedic surgical ward patients who underwent major surgery.\n\nExclusion Criteria:\n\n* Patients who require reoperation within 30 days.\n* Immunosuppressant patients.\n* Patients who are not adherent to the protocol time or dosing, either preoperatively, during, or postoperatively.\n* Pregnancy or breastfeeding.","ALL","18 Years",{"count":48,"type":49},100,"ESTIMATED","INTERVENTIONAL",[52],"PHASE4","A randomized controlled trial on adults who underwent orthopedic surgery. To evaluate the effectiveness of intraoperative continuous infusion (CI) of cefazolin compared with intermittent (INT) cefazolin administration in preventing SSIs in the orthopedic surgical population.\n\nEligible patients will be randomized in a block design into 2 groups: intervention and control. The intervention group will use continuous infusion of cefazolin (CI), while the control group will follow the traditional presurgical prophylaxis protocol of intermittent cefazolin doses (INT).",[55],"Surgical Site Infection (SSI)",[57,58],"cefazolin","orthopedic surgery","NOT_YET_RECRUITING","2026-06-19",{"date":62,"type":63},"2026-06-24","ACTUAL",{"date":65,"type":49},"2026-07-01",{"date":67,"type":49},"2026-12-31",{"name":5,"class":6}]